Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Ablynx, Taisho deal

    Ablynx N.V. (Euronext:ABLX), Ghent, Belgium Taisho Pharmaceutical Co. Ltd., Tokyo, Japan Business: Autoimmune Ablynx granted Taisho exclusive, Japanese rights to develop and commercialize ozoralizumab to treat …

    Published on 8/3/2015
  • Advanced Accelerator Applications, Fujifilm deal

    Advanced Accelerator Applications S.A., Saint Genis Pouilly, France Fujifilm Holdings Corp. (Tokyo:4901), Tokyo, Japan Business: Cancer Advanced Accelerator granted Fujifilms Fujifilm RI Pharma Co. Ltd. subsidiary …

    Published on 8/3/2015
  • Albany Molecular Research, SUNY Poly, PerkinElmer deal

    Albany Molecular Research Inc. (NASDAQ:AMRI), Albany, N.Y. State University of New York Polytechnic Institute, Utica, N.Y. PerkinElmer Inc. (NYSE:PKI), Waltham, Mass. Business: Supply/Service, High throughput screening …

    Published on 8/3/2015
  • Amarna Therapeutics, CBMed deal

    Amarna Therapeutics B.V., CH Leiden, the Netherlands Center for Biomarker Research in Medicine (CBmed), Graz, Austria Business: Cancer, Cardiovascular, Endocrine/Metabolic Amarna and CBmed partnered to develop …

    Published on 8/3/2015
  • Anacor, Novartis deal

    Anacor Pharmaceuticals Inc. (NASDAQ:ANAC), Palo Alto, Calif. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Infectious Anacor and Novartis Sandoz Inc. generics unit amended a 2014 deal granting Sandoz …

    Published on 8/3/2015
  • Ariad, PDL BioPharma deal

    Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Cambridge, Mass. PDL BioPharma Inc. (NASDAQ:PDLI), Incline Village, Nev. Business: Cancer Ariad will receive $100 million from PDL in exchange for royalties on future sales of …

    Published on 8/3/2015
  • AstraZeneca, INSERM deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. French National Institute of Health and Medical Research, Paris, France Business: Renal, Endocrine/Metabolic AstraZeneca and The French National Institute of Health and …

    Published on 8/3/2015
  • Bristol-Myers, Allied Minds, Harvard deal

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Allied Minds plc (LSE:ALM), Boston, Mass. Harvard University, Cambridge, Mass. Business: Autoimmune The university granted Allied-Bristol Life Sciences LLC, a JV …

    Published on 8/3/2015
  • Broda Tech, Redwood Pharma deal

    Broda Technologies Co. Ltd., Shanghai, China Redwood Pharma AB, Stockholm, Sweden Business: Drug delivery, Ophthalmic Broda granted Redwood exclusive, worldwide rights to use IntelliGel supramolecular hydrogel …

    Published on 8/3/2015
  • Caladrius Biosciences, University of Southern California, California Institute of Technology deal

    Caladrius Biosciences Inc. (NASDAQ:CLBS), New York, N.Y. University of Southern California, Los Angeles, Calif. California Institute of Technology, Pasadena, Calif. Business: Cancer, Gene/Cell therapy Caladrius, the …

    Published on 8/3/2015
  • cCAM Biotherapeutics, Merck deal

    cCAM Biotherapeutics Ltd., Misgav, Israel Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Cancer Merck will acquire cCAM for $95 million in cash plus up to $510 million in undisclosed development, regulatory and…

    Published on 8/3/2015
  • Chiome, ADC Therapeutics deal

    Chiome Bioscience Inc. (Tokyo:4583), Tokyo, Japan ADC Therapeutics S.a.r.l., Lausanne, Switzerland Business: Cancer Chiomes LivTech Inc. subsidiary granted ADC an option for exclusive, worldwide rights to develop LIV-…

    Published on 8/3/2015
  • Cyclacel, ManRos Therapeutics deal

    Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC), Berkeley Heights, N.J. ManRos Therapeutics S.A., Roscoff, France Business: Pulmonary Cyclacel granted ManRos exclusive, worldwide rights to develop and commercialize oral …

    Published on 8/3/2015
  • DNX Biopharmaceuticals, XL-protein deal

    DNX Biopharmaceuticals Inc., Irvine, Calif. XL-protein GmbH, Freising, Germany Business: Ophthalmic, Endocrine/Metabolic The companies partnered to develop and commercialize long-acting biopharmaceutical products. XL-…

    Published on 8/3/2015
  • Eli Lilly, Dana-Farber Cancer Institute deal

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Dana-Farber Cancer Institute, Boston, Mass. Business: Cancer Lilly and the institute partnered to research and develop undisclosed early stage cancer compounds and …

    Published on 8/3/2015
  • Eli Lilly, Sarah Cannon Research Institute deal

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Sarah Cannon Research Institute, Nashville, Tenn. Business: Cancer Lilly and the institute partnered to co-develop Lillys cancer compound LY3023414. SCRI will provide …

    Published on 8/3/2015
  • Eolas, AstraZeneca deal

    Eolas Therapeutics Inc., Carlsbad, Calif. AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Neurology Eolas granted AstraZeneca exclusive, worldwide rights to develop and commercialize an orexin 1 receptor (…

    Published on 8/3/2015
  • Faron Pharmaceuticals, Turku PET Centre deal

    Faron Pharmaceuticals Ltd., Turku, Finland Turku PET Centre, Turku, Finland Business: Cancer Faron and the Turku PET Centre partnered to develop Farons Clevegen, a preclinical immunotherapeutic for cancer. The center …

    Published on 8/3/2015
  • GlycoMimetics, Pfizer deal

    GlycoMimetics Inc. (NASDAQ:GLYC), Gaithersburg, Md. Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Hematology GlycoMimetics received a $20 million milestone payment from Pfizer under an October 2011 deal granting the …

    Published on 8/3/2015
  • Hanmi Pharmaceutical, Boehringer Ingelheim deal

    Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940), Seoul, South Korea Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Cancer Hanmi granted Boehringer exclusive, worldwide rights, excluding South Korea, China and …

    Published on 8/3/2015
  • Hebrew University of Jerusalem, Immune Pharmaceuticals deal

    Hebrew University of Jerusalem, Jerusalem, Israel Immune Pharmaceuticals Inc. (NASDAQ:IMNP;SSE:IMNP), New York, N.Y. Business: Neurology Yissum, the tech transfer arm of the university, granted Immune exclusive, …

    Published on 8/3/2015
  • Hemostemix, Ludwig Boltzmann Institute deal

    Hemostemix Inc. (TSX:HEM), Calgary, Alberta Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Vienna, Austria Business: Cardiovascular Hemostemix and Ludwig Boltzmann Institute (LBI) partnered to …

    Published on 8/3/2015
  • Immunovaccine, Incyte deal

    Immunovaccine Inc. (TSX:IMV;OTCQX:IMMVF), Halifax, Nova Scotia Incyte Corp. (NASDAQ:INCY), Wilmington, Del. Business: Cancer The companies partnered non-exclusively to evaluate Immunovaccines DPX-Survivac in combination…

    Published on 8/3/2015
  • Intrexon, Oragenics deal

    Intrexon Corp. (NYSE:XON), Germantown, Md. Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla. Business: Other Intrexon granted Oragenics exclusive, worldwide rights to develop and commercialize biotherapeutics based on the …

    Published on 8/3/2015
  • Invenra, Oxford BioTherapeutics deal

    Invenra Inc., Madison, Wis. Oxford BioTherapeutics Ltd., Abingdon, U.K. Business: Cancer Invenra and Oxford partnered to identify and characterize a panel of human mAbs against an undisclosed cancer target that Oxford …

    Published on 8/3/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993